Acasă › Cancer de sân › Wisconsin › Madison
Studii clinice pentru Cancer de sân în Madison, WI
22 studii pentru Cancer de sân caută participanți în și în jurul orașului Madison (în aproximativ 50 km). Deschideți un studiu pentru a vedea criteriile de eligibilitate și cum să contactați echipa de cercetare.
Text oficial al studiului (în engleză)
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
În curs de recrutareFaza 3
- University of Wisconsin Carbone Cancer Center- University Hospital, Madison
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
În curs de recrutareFaza 1/2
- University of Wisconsin Carbone Cancer Center, Madison
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
În curs de recrutareFaza 2
- UW Health Carbone Cancer Center, Madison
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
În curs de recrutareStudiu observaționalVoluntari sănătoși bineveniți
- William S Middleton VA Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
În curs de recrutareFaza 2
- University of Wisconsin, Madison
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
În curs de recrutareFaza 1
- Wisconsin Institute for Medical Research, Madison
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
În curs de recrutareFaza 3
- Circuit Clinical/SSM Health Dean Medical Group ( Site 0039), Madison
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
În curs de recrutareFaza 3
- University Hospital and UW Health Clinics-Carbone Cancer Center ( Site 0040), Madison
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
În curs de recrutareFaza 3
- University of Wisconsin-Madison ( Site 0024), Madison
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
În curs de recrutare
- University of Wisconsin, Madison
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
În curs de recrutareFaza 1
- University of Wisconsin - Carbone Cancer Center, Madison
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
În curs de recrutareFaza 3
- University of Wisconsin Carbone Cancer Center- University Hospital, Madison
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
În curs de recrutareFaza 1/2
- University of Wisconsin-Madison Carbone Cancer Center, Madison
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
În curs de recrutareFaza 2
- University of Wisconsin, Madison
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
În curs de recrutareFaza 3
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Study of 18F-FFNP Breast PET/MRI
În curs de recrutareFaza 2
- UW Carbone Cancer Center, Madison
Biomarkers to Detect Endocrine Therapy Resistance
În curs de recrutareFaza 2
- UW Carbone Cancer Center, Madison
Real-Time MRI-Guided 3-Fraction Accelerated Partial Breast Irradiation in Early Breast Cancer
În curs de recrutareFaza 2
- University of Wisconsin Carbone Cancer Center, Madison
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
În curs de recrutareFaza 3
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
În curs de recrutareStudiu observațional
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
În curs de recrutareFaza 4
- University of Wisconsin, Madison
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
În curs de recrutareFaza 1
- UW Carbone Cancer Center, Madison
Studii pentru Cancer de sân în alte orașe
- New York City, NY136 studii
- Houston, TX126 studii
- Boston, MA112 studii
- Nashville, TN81 studii
- Los Angeles, CA73 studii
- Edison, NJ68 studii
- St. Louis, MO64 studii
- Queens, NY64 studii
- Durham, NC64 studii
- Chicago, IL59 studii
- Philadelphia, PA56 studii
- Dallas, TX55 studii
Alte studii în Madison
- Cancer de prostată29 studii
- Cancer colorectal23 studii
- Cancer metastatic21 studii
- Leucemie mieloasă acută16 studii
- Cancer pulmonar cu celule non-pătrate16 studii
- Melanom15 studii
- Cancer (toate tipurile)14 studii
- Cancer ovarian13 studii
- Cancer gastric11 studii
- Cancer pancreatic10 studii
- Cancer pulmonar10 studii
- Mielom multiplu9 studii
Sursă: ClinicalTrials.gov, date preluate la 6 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.